MX2022003945A - Metodo para tratar vih con cabotegravir y rilpivirina. - Google Patents

Metodo para tratar vih con cabotegravir y rilpivirina.

Info

Publication number
MX2022003945A
MX2022003945A MX2022003945A MX2022003945A MX2022003945A MX 2022003945 A MX2022003945 A MX 2022003945A MX 2022003945 A MX2022003945 A MX 2022003945A MX 2022003945 A MX2022003945 A MX 2022003945A MX 2022003945 A MX2022003945 A MX 2022003945A
Authority
MX
Mexico
Prior art keywords
cabotegravir
rilpivirine
treat hiv
human
pharmaceutically acceptable
Prior art date
Application number
MX2022003945A
Other languages
English (en)
Spanish (es)
Inventor
Herta Maria Ludovica Crauwels
Susan L Ford
David Andrew Margolis
Stefaan Louis F Rossenu
William Robert Spreen
Solingen-Ristea Rodica Mihaela Van
Peter Evan Owen Williams
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of MX2022003945A publication Critical patent/MX2022003945A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022003945A 2019-10-01 2020-10-01 Metodo para tratar vih con cabotegravir y rilpivirina. MX2022003945A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908882P 2019-10-01 2019-10-01
US201962908995P 2019-10-01 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US202063052214P 2020-07-15 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (1)

Publication Number Publication Date
MX2022003945A true MX2022003945A (es) 2022-04-25

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003945A MX2022003945A (es) 2019-10-01 2020-10-01 Metodo para tratar vih con cabotegravir y rilpivirina.

Country Status (11)

Country Link
US (3) US20220347174A1 (https=)
EP (1) EP4037661A1 (https=)
JP (1) JP7791083B2 (https=)
KR (1) KR20220074880A (https=)
CN (2) CN118416069A (https=)
AU (1) AU2020358156B2 (https=)
CA (1) CA3155587A1 (https=)
CL (1) CL2022000790A1 (https=)
IL (1) IL290716A (https=)
MX (1) MX2022003945A (https=)
WO (1) WO2021064618A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2480220T3 (pl) * 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
KR20200031658A (ko) * 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Also Published As

Publication number Publication date
US20250302830A1 (en) 2025-10-02
AU2020358156B2 (en) 2024-06-06
IL290716A (en) 2022-04-01
CA3155587A1 (en) 2021-04-08
WO2021064618A1 (en) 2021-04-08
EP4037661A1 (en) 2022-08-10
KR20220074880A (ko) 2022-06-03
CN118416069A (zh) 2024-08-02
US20250302829A1 (en) 2025-10-02
CN114502166A (zh) 2022-05-13
JP2022550828A (ja) 2022-12-05
JP7791083B2 (ja) 2025-12-23
CL2022000790A1 (es) 2022-11-25
AU2020358156A1 (en) 2022-04-21
US20220347174A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
MX2022000143A (es) Metodos novedosos.
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CO2020010013A2 (es) Terapia de combinación para tratar o prevenir el cáncer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131